229 related articles for article (PubMed ID: 11685723)
1. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
Berry W; Dakhil S; Gregurich MA; Asmar L
Semin Oncol; 2001 Aug; 28(4 Suppl 15):8-15. PubMed ID: 11685723
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
5. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
[TBL] [Abstract][Full Text] [Related]
6. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Sitka Copur M; Ledakis P; Lynch J; Hauke R; Tarantolo S; Bolton M; Norvell M; Muhvic J; Hake L; Wendt J
Semin Oncol; 2001 Aug; 28(4 Suppl 15):16-21. PubMed ID: 11685724
[TBL] [Abstract][Full Text] [Related]
7. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Hussain A; Dawson N; Amin P; Naslund M; Engstrom C; Chen T
Semin Oncol; 2001 Aug; 28(4 Suppl 15):22-31. PubMed ID: 11685725
[TBL] [Abstract][Full Text] [Related]
9. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Gravis G; Bladou F; Salem N; Macquart-Moulin G; Serment G; Camerlo J; Genre D; Bardou VJ; Maraninchi D; Viens P
Cancer; 2003 Oct; 98(8):1627-34. PubMed ID: 14534878
[TBL] [Abstract][Full Text] [Related]
10. Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients.
Kojima T; Shimazui T; Onozawa M; Tsukamoto S; Hinotsu S; Miyanaga N; Hattori K; Kawai K; Akaza H
Jpn J Clin Oncol; 2004 Mar; 34(3):137-41. PubMed ID: 15078909
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
Tester W; Ackler J; Tijani L; Leighton J
Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Ansari J; Hussain SA; Zarkar A; Tanguay JS; Bliss J; Glaholm J
Oncol Rep; 2008 Oct; 20(4):891-6. PubMed ID: 18813832
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.
Beer TM; Pierce WC; Lowe BA; Henner WD
Ann Oncol; 2001 Sep; 12(9):1273-9. PubMed ID: 11697840
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
[TBL] [Abstract][Full Text] [Related]
17. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
Beer TM; Eilers KM; Garzotto M; Egorin MJ; Lowe BA; Henner WD
J Clin Oncol; 2003 Jan; 21(1):123-8. PubMed ID: 12506180
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
Weitzman AL; Shelton G; Zuech N; Owen CE; Judge T; Benson M; Sawczuk I; Katz A; Olsson CA; Bagiella E; Pfaff C; Newhouse JH; Petrylak DP
J Urol; 2000 Mar; 163(3):834-7. PubMed ID: 10687988
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
20. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
